摘要
为评价重组禽流感病毒二价灭活疫苗(H5N1 Re-8株+H7N9 Re-1株)在商品肉鹅中的安全性和有效性,各取200只肉鹅进行单剂量和大剂量安全试验,另取500只进行免疫效力试验。结果显示:接种大剂量疫苗试验组的鹅,采食、饮水及精神状况正常,未见有不良临床反应,注射部位肌肉均未观察到炎症、疫苗残留现象,疫苗吸收良好,增重差异不明显。效力试验中,加强免疫后2周,抗体合格率达70%以上,病毒分离均为阴性。结果表明,该重组禽流感病毒二价灭活疫苗具有较好的安全性和有效性。建议对2周龄雏鹅进行首免,每只注射0.5 mL,5周龄时加强免疫1次,每只1.5 mL,这样可取得较好的免疫保护效果。
In order to scientifically evaluate the security and effectiveness of divalent inactivated vaccine of recombinant avian influenza(H5N1 Re-8+H7N9 Re-1 strain)on the commercial meat geese,400 geese were taken for single-dose and high-dose safety tests,500 geese were taken for immune effectiveness tests.The results showed that those geese injected with high dose of vaccines had a normal status in eating food,drinking water and in mental state,no clinical adverse reaction was observed.Besides,for the muscles at the injection sites,no inflammation and vaccine residue phenomenon was observed.The absorption of vaccine was good,and the difference between weight gains was not obvious.In terms of immune effectiveness test,2 weeks after booster immunization,the antibody qualification rate was over 70%,and all the virus isolation tests showed a negative result.As a conclusion,the recombinant avian influenza virus(H5+H7)vaccine had characteristics of good safety and effectiveness.It was recommended that first immunization should be carried out towards geese of 2 weeks old(injecting 0.5 mL vaccine for each goose),and booster immunization should be given when the goose was 5 weeks old,with the dosage of 1.5 mL,by which good immune effects could be obtained.
作者
谢向萌
韦显凯
梁晟
覃小柳
梁仕增
闭璟珊
袁湖业
胡茂快
Xie Xiangmeng;Wei Xiankai;Liang Sheng;Qin Xiaoliu;Liang Shizeng;Bi Jingshan;Yuan Huye;Hu Maokuai(Hengxian Animal Disease Control and Prevention Center,Hengxian,Guangxi 530300,China;Guangxi Animal Disease Control and Prevention Center,Nanning,Guangxi 530001,China;Agricultural Station of Taoxu Town,Hengxian,Guangxi 530314,China)
出处
《中国动物检疫》
CAS
2018年第8期76-80,共5页
China Animal Health Inspection
关键词
重组禽流感病毒
灭活疫苗
H7N9
安全性
有效性
recombinant avian influenza virus
inactivated vaccine
H7N9
security
effectiveness
